Prosthesis–Patient Mismatch after Aortic Valve Replacement with the Mosaic Ultra Bioprosthesis

Abstract

Background Several studies have reported high rates of prosthesis–patient mismatch (PPM) after aortic valve replacement (AVR) with the Mosaic prosthesis. This work assesses the incidence of PPM after AVR with a modified version of the Mosaic prosthesis, the Mosaic Ultra.

Methods We performed a retrospective analysis of the data of 532 patients who underwent AVR with implantation of the Mosaic Ultra prosthesis in the period 2007–2016 in our institution. Patients were classified according to their indexed effective orifice area (EOAi) to severe (EOAi < 0.65 cm²/m²), moderate (EOAi 0.65–0.85 cm²/m²), and absent/mild PPM (EOAi > 0.85 cm²/m²). In-hospital postoperative outcomes and the impact of PPM on mean transvalvular pressure gradient after stratification by prosthesis size were assessed.

Results Overall, 3 (0.6%) patients had severe, 92 (17.3%) moderate, and 437 (82.1%) absent/mild PPM. There was a significant difference in PPM proportions (moderate/severe vs absent/mild PPM) across different prosthesis sizes overall (p < 0.0001), observing gradually increasing rates of PPM with decreasing prosthesis sizes. Patients with moderate/severe PPM had higher mean transvalvular pressure gradients (19 [13–25] vs 13 [10–17] mm Hg, p < 0.0001) than patients with absent/mild PPM. There was a significant difference in mean transvalvular pressure gradient between the different aortic valve prosthesis sizes overall (p < 0.0001), observing gradually increasing gradients with decreasing prosthesis sizes.

Conclusion Patients undergoing AVR with the smaller sized (19, 21, and 23 mm) Mosaic Ultra aortic valve prostheses exhibit a higher risk for moderate/severe PPM and higher mean aortic transvalvular pressure gradients than patients receiving the larger sized (25, 27, and 29 mm) prostheses.

Keywords

aortic valve and root - heart valve surgery - outcomes

• References

• 1 Pibarot P, Dumesnil JG, Lemieux M, Cartier P, Métras J, Durand LG. Impact of prosthesis-patient mismatch on hemodynamic and symptomatic status, morbidity and mortality after aortic valve replacement with a bioprosthetic heart valve. J Heart Valve Dis 1998; 7 (02) 211-218
• 2 Pibarot P, Dumesnil JG. Prosthesis-patient mismatch: definition, clinical impact, and prevention. Heart 2006; 92 (08) 1022-1029
• 3 Bilkhu R, Jahangiri M, Otto CM. Patient-prosthesis mismatch following aortic valve replacement. Heart 2019; 105 (Suppl. 02) s28-s33
• 4 House CM, Nelson WB, Kroshus TJ, Dahiya R, Pibarot P. Manufacturer-provided effective orifice area index charts and the prevention of prosthesis-patient mismatch. J Heart Valve Dis 2012; 21 (01) 107-111
• 5 Anselmi A, Flécher E, Ruggieri VG. et al. Long-term results of the Medtronic Mosaic porcine bioprosthesis in the aortic position. J Thorac Cardiovasc Surg 2014; 147 (06) 1884-1891
• 6 Yoshikawa Y, Okada Y, Okita Y. et al. Long-term outcomes of the Mosaic aortic porcine bioprosthesis in Japan - results from the Japan Mosaic valve long-term multicenter study. Circ J 2020; 84 (08) 1261-1270
• 7 Rieß F-C, Fradet G, Lavoie A, Legget M. Long-term outcomes of the Mosaic bioprosthesis. Ann Thorac Surg 2018; 105 (03) 763-769
• 8 Glaser N, Franco-Cereceda A, Sartipy U. Late haemodynamic performance and survival after aortic valve replacement with the Mosaic bioprosthesis. Interact Cardiovasc Thorac Surg 2014; 19 (05) 756-762
• 9 Riess FC, Cramer E, Hansen L. et al. Clinical results of the Medtronic Mosaic porcine bioprosthesis up to 13 years. Eur J Cardiothorac Surg 2010; 37 (01) 145-153
• 10 Medtronic. Mosaic Cinch, Mosaic Ultra: Instructions for Use. Minneapolis, MN:
• 11 Braathen B, Husebye T, Lunde IG, Tønnessen T. Trifecta has lower gradient and less prosthesis-patient mismatch than Mosaic Ultra in the aortic position: a prospective randomized study. J Thorac Cardiovasc Surg 2019; 158 (04) 1032-1039
• 12 Domoto S, Niinami H, Uwabe K. et al. Comparison of early haemodynamics of 19-mm aortic valve bioprostheses in patients with a small aortic annulus. Interact Cardiovasc Thorac Surg 2016; 22 (01) 19-25
• 13 Fradet GJ, Bleese N, Burgess J, Cartier PC. Mosaic valve international clinical trial: early performance results. Ann Thorac Surg 2001; 71 (5, Suppl): S273-S277
• 14 Dalmau MJ, González-Santos JM, López-Rodríguez J, Bueno M, Arribas A, Nieto F. One year hemodynamic performance of the Perimount Magna pericardial xenograft and the Medtronic Mosaic bioprosthesis in the aortic position: a prospective randomized study. Interact Cardiovasc Thorac Surg 2007; 6 (03) 345-349
• 15 Botzenhardt F, Eichinger WB, Bleiziffer S. et al. Hemodynamic comparison of bioprostheses for complete supra-annular position in patients with small aortic annulus. J Am Coll Cardiol 2005; 45 (12) 2054-2060
• 16 Eichinger WB, Botzenhardt F, Keithahn A. et al. Exercise hemodynamics of bovine versus porcine bioprostheses: a prospective randomized comparison of the mosaic and perimount aortic valves. J Thorac Cardiovasc Surg 2005; 129 (05) 1056-1063
• 17 Glaser N, Franco-Cereceda A, Sartipy U. Late survival after aortic valve replacement with the perimount versus the mosaic bioprosthesis. Ann Thorac Surg 2014; 97 (04) 1314-1320
• 18 Pibarot P, Dumesnil JG. Hemodynamic and clinical impact of prosthesis-patient mismatch in the aortic valve position and its prevention. J Am Coll Cardiol 2000; 36 (04) 1131-1141
• 19 Rader F, Sachdev E, Arsanjani R, Siegel RJ. Left ventricular hypertrophy in valvular aortic stenosis: mechanisms and clinical implications. Am J Med 2015; 128 (04) 344-352
• 20 Rocha RV, Manlhiot C, Feindel CM. et al. Surgical enlargement of the aortic root does not increase the operative risk of aortic valve replacement. Circulation 2018; 137 (15) 1585-1594
• 21 Bach DS. Echo/Doppler evaluation of hemodynamics after aortic valve replacement: principles of interrogation and evaluation of high gradients. JACC Cardiovasc Imaging 2010; 3 (03) 296-304